Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80403.520.7051%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Braveheart Bio Inc

BRVENASDAQ
Trade with Public
Trade with Public
$26.74
0.471.79%
At close: Sep 4, 5:00 PM EST
$26.00
-0.74-2.77%
After Hours: Sep 4, 8:36 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Braveheart Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Braveheart Bio (BRVE).

Price Target Range — 1 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$45Upside to Avg. PT+74.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026Goldman SachsSalveen RichterInitiateBuy$48
Aug 31, 2026TD CowenTyler Van BurenInitiateBuy—
More with Benzinga EdgeGet Access

Analyst Ratings News

This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst
Avi Kapoor

PRO
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.
Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating

TD Cowen analyst Tyler Van Buren initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating.
Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

Jefferies initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.
Benzinga Newsdesk

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI
Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Overweight rating and announces Price Target of $40.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved